Current recommendations surrounding the administration of the second COVID-19 vaccine dose to patients who experience an immediate hypersensitivity reaction to the first dose are conflicting.
Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps.
The phase 2 Systemic Allergic Reactions to SARS-CoV-2 Vaccination trial will enroll 3400 adults aged 18 to 69 years.
Evidence suggests that most patients with penicillin allergy history could safely receive cefazolin for surgical prophylaxis
The bioelectronic device was previously approved for treating sinus pain due to allergic rhinitis.
Guidance relates to risks for allergic reactions for mRNA (Moderna and Pfizer) and adenovirus vector (Johnson & Johnson) COVID-19 vaccines
Most recipients with anaphylaxis had allergy histories, with 31 percent having prior anaphylaxis
Findings seen in a survey of U.S. adults with asthma during the COVID-19 pandemic
Researchers studied subgroups of patients with uncontrolled asthma to determine if cardiovascular risk would affect their response to umeclidinium added to fluticasone furoate/vilanterol.
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
